Monday.com Just Showed You What “Raised Outlook” Actually Costs — May 11, 2026
*Your daily premarket trade brief, brought to you by [SignalDeck.live](https://signaldeck.live).*
---
A project management software company is gapping 23% in premarket because it raised its full-year outlook, launched an AI work platform, and bought back half a billion in shares — all in one print. The biggest signal in our screen today isn’t subtle: MNDY combined squeeze fuel (15.7% short float, 6x premarket relative volume) with a clean beat and a guidance raise. That’s the kind of stack that doesn’t usually fade by lunch.
The secondary theme is more interesting: every name in today’s hottest sector cluster (semis, 84 average percentile, twelve consecutive sessions outperforming the broad market) just got rewarded for stories about *future* AI revenue, even when the current quarter was meh. Translation: institutions are paying for the next chapter, not this one.
## The Top Calls
- **MNDY (Monday.com)** · Software · +22.81% · EP-β 94 — Q1 revenue $351M beat by 4%, full-year outlook raised, AI Work Platform launched with native agents and consumption-based pricing, plus $552M share buyback. Short interest 15.7% with premarket relative volume above 6x is the classic squeeze setup we look for. Days-to-cover 3.5 is moderate; the squeeze isn’t a one-day cascade so much as multi-day pressure. R/R favors holding the gap through midday — if buyers from premarket get run over by sellers at open, that’s the tell. We expect the opposite.
- **CRON (Cronos Group)** · Cannabis · +11.42% · EP-β 73 — Q1 revenue $45M +40% YoY, net income +103%, new $50M buyback, international revenue outside Israel +97% YoY. Days-to-cover 6.7 on a $3 stock with 4x relative volume is the kind of setup small accounts can actually trade. The catalyst stack — growth + capital return + international momentum — is unusually clean for a cannabis name. Cash position $821M means the buyback isn’t a stretch; it’s a credible signal management thinks the stock is undervalued at $2.83.
- **CEVA (Ceva Inc)** · Semiconductors · +12.09% · EP-β 69 — On paper this looked like a fade: EPS narrowly missed at $0.18 vs $0.19 estimate. But the stock is up 12% because the AI royalty narrative is the story now, not Q1. Ten new AI chip design agreements signed last year. Six customers expected to have silicon shipping by end of 2026. AI now contributes 20% of licensing revenue. Combine that with a 96.8 individual momentum percentile (top 4% of the universe) sitting inside the hottest sector cluster on our board, and you get the kind of mismatch where the EPS miss becomes a buying opportunity. This is the “EPS miss, story beat” trade.
- **HIMX (Himax Technologies)** · Semiconductors · +8.83% · EP-β 67 — Reported Thursday 5/7. Q1 was fine, but the Q2 guide is the real news: revenue up 10-13% sequentially, gross margin to 32%, EPS roughly doubling to $0.086-$0.103. Stock has a 99.4 momentum percentile (literally top 1% of the universe). Same hot semis cluster as CEVA. Plus an automotive ramp expected in the second half of 2026 and a WiseEye AI thesis still under-priced by the street. We’ve been watching this name on the back burner for a week — today it promoted itself to the active list.
- **BW (Babcock & Wilcox)** · Power Equipment · +14.10% · EP-β 60 — Revenue up 44% YoY to $214M, adjusted EBITDA $16M vs $4M prior year (a 4x), bookings $2.5B, backlog $2.7B, total pipeline north of $14B. The headline GAAP loss is a non-cash warrant valuation distraction — the operating business is firing. The catch: this lives in a cold sector (industrials averaging 49 momentum percentile) and BW itself is at 30. The story is real; the tape isn’t ready. This is a swing-trade setup, not a Phase-2 entry.
> Watch the first 30 minutes. MNDY’s premarket strength is the most volume-confirmed gap in the alert. If it opens green and holds positive change-from-open, the squeeze setup is firing. If it gaps up and immediately reverses below the open, that’s the distribution-day pattern we got burned on with DAVE last week — sellers using the gap to exit. Same playbook applies to all five names today.
## The Quiet Beats
Today’s pre-market screener didn’t surface obvious “muted reaction to a real beat” candidates — most of today’s reporters either gapped hard or sat out entirely. But three names from last Tuesday’s earnings batch are sitting in their R10.1 Day 4 re-acceleration window today, and one of them is the most under-priced setup on our board:
- **IONQ (Quantum Computing)** · Computer Hardware · Momentum 97 — Reported a 481% EPS surprise and 53% revenue growth last Tuesday but barely gapped after-hours. The pattern we’ve documented (and back-tested): when institutions can’t size into thin extended-hours liquidity, they buy on Day 4-6 instead. IONQ’s day-1 through day-3 was textbook absorption: shake the weak hands, build the position. Today is Day 4. If today’s session opens flat and tight, this is the optimal entry zone. If it breaks out hard (already up more than 5% at the open), you’re late but the thesis is firing.
- **HNGE (Hinge Health)** · Digital Health · Momentum 97 — Already up 12.7% from last week’s entry, sitting at the bottom of our day-5 target band. Day 4 today. If it pulls back to a flat consolidation zone, that’s the second-entry trigger.
- **APO (Apollo Global)** · Asset Management · Momentum 79 — Asset allocators don’t trade on after-hours algorithms. They trade Monday morning at the desk. APO’s Friday close was +4.2% — the pattern is engaging on the right cadence for its archetype. Slow money compounds over a week, not a session.
> R10.1 says Day 4-7 after a high-conviction earnings print is the optimal re-entry window. AMD and SMCI from the same cohort already ran (+28% and +27% by Day 3 respectively) — late to those names now. IONQ is the one still un-priced.
## Yesterday’s Lessons
- **HIMX watchlist closure** — We projected the post-earnings R10.1 trigger for 5/13. It fired today instead on Day 2. Lesson: when the Q2 guide is dramatically raised (EPS doubling quarter-over-quarter), institutions don’t wait for the absorption window. They buy the print directly. Adjust R10.1 priors: if guide raise is *aggressive* (vs just maintained), expect earlier re-acceleration.
- **TNET fakeout** — Stock printed +13% in premarket on 129 shares of total premarket volume. Earnings were two weeks ago. Lesson: always inspect the volume number before getting excited about a percent change — a +13% gap on 129 shares is a quote artifact, not a trade.
- **The catch-all pass earned its keep again** — Pass 1 ( “known reporters”) returned 9 stocks. Pass 2 (catch-all gap ≥5%) returned 31. The delta included QCOM (R10.1 Day 9 continuation on a new $20B buyback + hyperscaler AI win), HIMX ( missed the earnings tag), and several biotech catalysts. Without Pass 2, we’d have missed the watchlist closure. Two-pass scan stays.
## The Read
**Best risk-adjusted trade today:** MNDY. Cleanest setup in the alert — beat, raised guide, new product, buyback, squeeze fuel, and the highest premarket volume confirmation. The story is unambiguous and the tape is doing the work.
**Highest-upside speculative trade:** CRON on the $3 base. Days-to-cover 6.7 on a small-cap with 4x relative volume and a fresh buyback isn’t a normal setup. If it holds the gap into the afternoon, the next-leg odds are good. Small-account friendly.
**Best two-week compounding trade:** IONQ — if today’s open is flat-and-tight, this is the R10.1 Day 4 entry. Same setup that paid +28% on AMD over three days. Risk is the day count being off; size accordingly.
**Don’t chase:** TH. EBITDA beat and a raised guide sound great, but the top line missed, EPS missed, and the premarket gap is on basically no volume. This is the textbook distribution-day-risk pattern. Wait for the open to confirm with real volume before touching it.
**Lesson banked:** Aggressive guide raises (EPS doubling-class) compress the R10.1 absorption window. Update playbook to differentiate “maintained-after-beat” prints (slow R10.1 fire on Day 4-6) from “structurally raised” prints (instant institutional bid, Day 1-2 re-rate). HIMX is the seed example.
---
**Not financial advice.** This is independent market analysis and momentum research, not a recommendation to buy or sell anything. Markets are volatile, individual securities can lose 100% of their value, and past performance does not predict future results. Do your own due diligence, size positions you can afford to lose, and consult a licensed financial advisor before making investment decisions. Your money, your risk, your call.